Ventripoint to launch reference site program

TORONTO – Ventripoint Diagnostics Ltd., a provider of innovative cardiac diagnostic solutions, is pleased to announce the launch of its new reference site program. This initiative aims to foster collaboration with key stakeholders in major hospitals to enhance the accuracy, efficiency and diagnostic capabilities of echocardiography.

By engaging with healthcare professionals at the forefront of cardiac care, Ventripoint seeks to continue to gain invaluable insights into the clinical needs and challenges faced in everyday practice. This collaborative approach will enable the company to continuously improve VMS+ to meet the evolving demands of the healthcare landscape and deliver optimal patient outcomes.

Ventripoint is currently in discussions with candidate sites and over the next few months will announce the institutions and further information regarding the scope of these relationships.

The reference site program will provide participating hospitals with early access to VMS+ technology, expert training, and ongoing support. Ventripoint is committed to working closely with these partners to ensure the successful implementation and utilization of VMS+ within their routine clinical workflows. Partner sites will provide greater local visibility of the capabilities of VMS+ and enable more effective peer-to-peer communication regarding adoption of the technology.

“Working closely with clinical experts has been core to everything we do at Ventripoint since the company’s founding at the University of Washington,” said Ventripoint’s CEO Hugh MacNaught (pictured). “The reference site programme brings us closer to renowned centres of cardiac excellence in the United States, Europe, the UK and Canada. It will provide the opportunity for us to expand applications of our technology to new patient groups and demonstrate value-in-use through more timely treatment decisions and improved patient outcomes.”